A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor

Trial Profile

A Phase I Dose Escalation Study of MK1496 in Patients With Advanced Solid Tumor

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Feb 2015

At a glance

  • Drugs MK 1496 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 25 Oct 2012 Actual end date changed from Dec 2010 to Jan 2011 as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Feb 2011 Actual end date changed from Jun 2011 to Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top